We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Criminal and financial penalties against pharmaceutical manufacturers continued a downward trend in the past two years and financial penalties for unlawful promotion dropped dramatically since 2013, according to Public Citizen, in a new analysis of federal and state settlements from 1991 to 2017. Read More
Judge John Z. Lee of the Northern District of Illinois wrote that the higher prices Walgreens reported to insurers constituted false factual statements. Read More
Pay-for-delay deals between branded and generic drugmakers in the European Union continued to decline in 2016, according to the latest update from the European Commission. Read More
Generic manufacturer Impax Laboratories agreed to pay $35 million to settle pay-for-delay lawsuits brought by a class of direct purchasers of the acne medication Solodyn (minocycline), sold by Medicis Pharmaceutical, a unit of Valeant. Read More
Oxycodone, hydrocodone, fentanyl and morphine products accounted for less than 25 percent of opioids sold between 1992 and 1995, but reached an 80 percent share by 2011. Read More
Opioid sales increased more than eightfold between 1992 and 2015, according to a new analysis by the FDA that found no clear links between price and volume. Read More